ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2026
Evaluation of the Antifibrotic and Functional Effects of Pirfenidone in an Experimental Frozen Shoulder Model.
Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the histopathological and functional effects of pirfenidone in a rat model of frozen shoulder (adhesive capsulitis). Thirty-two male Wistar Albino rats were randomly divided into four groups (n = 8 each): control, frozen shoulder (FS), pirfenidone-treated (FS + PFD), and dexamethasone-treated (FS + DEX). The FS model was induced by immobilizing the shoulder joint with plaster for 4 weeks. Treatment groups received oral pirfenidone (30 mg/kg/day) or prednisolone (3 mg/kg/day) for 30 days. Histopathological changes in the synovial membrane and fibrous capsule were evaluated with hematoxylin-eosin and Masson's trichrome staining, while shoulder joint range of motion (ROM) was measured. The FS group showed significant pathological alterations, including synovial epithelial atrophy, loss of synovial folds, hyperemia, edema, and severe capsular fibrosis. Both pirfenidone and dexamethasone treatments reduced these abnormalities. Pirfenidone was more effective in preserving collagen fiber organization and synovial fold integrity. ROM was markedly reduced in the FS group, but partial recovery occurred in both treatment groups. Pirfenidone provided greater functional improvement compared with dexamethasone. Inflammation scores did not differ significantly between groups, consistent with evaluation during the fibrotic phase. Pirfenidone attenuates fibrotic changes and improves joint mobility in an experimental frozen shoulder model. Pirfenidone improved histological fibrosis scores and ROM in this experimental model. Comparative effectiveness versus corticosteroids requires confirmation in larger, appropriately powered studies. These results emphasize the antifibrotic potential of pirfenidone and support further long-term and clinical studies to clarify its role in adhesive capsulitis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.